Your browser doesn't support javascript.
loading
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Martin, Allison M; Nirschl, Christopher J; Polanczyk, Magda J; Bell, W Robert; Nirschl, Thomas R; Harris-Bookman, Sarah; Phallen, Jillian; Hicks, Jessica; Martinez, Daniel; Ogurtsova, Aleksandra; Xu, Haiying; Sullivan, Lisa M; Meeker, Alan K; Raabe, Eric H; Cohen, Kenneth J; Eberhart, Charles G; Burger, Peter C; Santi, Mariarita; Taube, Janis M; Pardoll, Drew M; Drake, Charles G; Lim, Michael.
Afiliación
  • Martin AM; Johns Hopkins School of Medicine, Sidney Kimmel Cancer Center, Division of Pediatric Oncology, Baltimore, MD, USA.
  • Nirschl CJ; Johns Hopkins School of Medicine, Sidney Kimmel Cancer Center, Division of Cancer Immunology, Baltimore, MD, USA.
  • Polanczyk MJ; Johns Hopkins School of Medicine, Sidney Kimmel Cancer Center, Division of Pediatric Oncology, Baltimore, MD, USA.
  • Bell WR; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN, USA.
  • Nirschl TR; Johns Hopkins School of Medicine, Department of Pathobiology, Baltimore, MD, USA.
  • Harris-Bookman S; Johns Hopkins School of Medicine, Department of Ophthalmology, Baltimore, MD, USA.
  • Phallen J; Johns Hopkins School of Medicine, Sidney Kimmel Cancer Center, Division of Cancer Biology, Baltimore, MD, USA.
  • Hicks J; Johns Hopkins School of Medicine, Department of Pathology, Division of Kidney and Urologic Pathology, Baltimore, MD, USA.
  • Martinez D; Children's Hospital of Philadelphia, Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA.
  • Ogurtsova A; Johns Hopkins School of Medicine, Department of Dermatology, Division of Dermatologic Pathology and Oral Pathology, Baltimore, MD, USA.
  • Xu H; Johns Hopkins School of Medicine, Department of Dermatology, Division of Dermatologic Pathology and Oral Pathology, Baltimore, MD, USA.
  • Sullivan LM; In Jackson, MS, USA.
  • Meeker AK; Johns Hopkins School of Medicine, Department of Pathology, Division of Kidney and Urologic Pathology, Baltimore, MD, USA.
  • Raabe EH; Johns Hopkins School of Medicine, Sidney Kimmel Cancer Center, Division of Pediatric Oncology, Baltimore, MD, USA.
  • Cohen KJ; Johns Hopkins School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, MD, USA.
  • Eberhart CG; Johns Hopkins School of Medicine, Sidney Kimmel Cancer Center, Division of Pediatric Oncology, Baltimore, MD, USA.
  • Burger PC; Johns Hopkins School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, MD, USA.
  • Santi M; Johns Hopkins School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, MD, USA.
  • Taube JM; Children's Hospital of Philadelphia, Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA.
  • Pardoll DM; Johns Hopkins School of Medicine, Department of Dermatology, Division of Dermatologic Pathology and Oral Pathology, Baltimore, MD, USA.
  • Drake CG; Johns Hopkins School of Medicine, Sidney Kimmel Cancer Center, Division of Cancer Immunology, Baltimore, MD, USA.
  • Lim M; Columbia University Medical Center, Division of Hematology/Oncology, New York, NY, USA.
Oncotarget ; 9(27): 19177-19191, 2018 Apr 10.
Article en En | MEDLINE | ID: mdl-29721192
BACKGROUND: This study evaluated the expression of PD-L1 and markers of immune mediated resistance in human medulloblastoma (MB), the most common malignant pediatric brain tumor. RESULTS: Overall levels of PD-L1 in human MB were low; however, some cases demonstrated robust focal expression associated with increased immune infiltrates. The case with highest PD-L1 expression was a sonic hedgehog (SHH) MB. In cell lines, SHH MB, which are low-MYC expressing, demonstrated both constitutive and inducible expression of PD-L1 while those in Group 3/4 that expressed high levels of MYC had only inducible expression. In vitro, IFN-γ robustly stimulated the expression of PD-L1 in all cell lines while radiation induced variable expression. Forced high MYC expression did not significantly alter PD-L1. METHODS: Human MB tumor samples were evaluated for expression of PD-L1 and immune cell markers in relation to molecular subgroup assignment. PD-L1 expression was functionally analyzed under conditions of interferon gamma (IFN-γ), radiation, and MYC overexpression. CONCLUSIONS: MB expresses low levels of PD-L1 facilitating immune escape. Importantly, TH1 cytokine stimulation appears to be the most potent inducer of PD-L1 expression in vitro suggesting that an inflamed tumor microenvironment is necessary for PD-1 pathway activation in this tumor.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos